| Literature DB >> 27129305 |
Christopher Kurz1,2, Reinoud Nijhuis1, Michael Reiner1, Ute Ganswindt1, Christian Thieke1, Claus Belka1, Katia Parodi2, Guillaume Landry3,4.
Abstract
BACKGROUND: Intensity modulated proton therapy (IMPT) of head and neck (H&N) tumors may benefit from plan adaptation to correct for the dose perturbations caused by weight loss and tumor volume changes observed in these patients. As cone beam CT (CBCT) is increasingly considered in proton therapy, it may be possible to use available CBCT images following intensity correction for plan adaptation. This is the first study exploring IMPT plan adaptation on CBCT images corrected and delineated by deformable image registration of the planning CT (pCT) to the CBCT, yielding a virtual CT (vCT).Entities:
Keywords: Adaptive radiation therapy; Cone beam CT; Deformable image registration; Head and neck cancer; Intensity modulated proton therapy
Mesh:
Year: 2016 PMID: 27129305 PMCID: PMC4851791 DOI: 10.1186/s13014-016-0641-7
Source DB: PubMed Journal: Radiat Oncol ISSN: 1748-717X Impact factor: 3.481
Patient characteristics. ΔtrpCT and ΔtCBCT are the times between planning and replanning CT acquisition and between planning CT and CBCT acquisition respectively
| Patient identifier | Age | Sex | Tumor site | TNM stage | ΔtrpCT (days) | ΔtCBCT (days) | SIB prescription low dose/high dose (Gy) | Number of SIB fractions |
|---|---|---|---|---|---|---|---|---|
| Pat1 | 65 | M | Larynx | pT2pN0M0 | 51 | 50 | 50/- | 25 |
| Pat2 | 54 | F | Hypopharynx, esophagus | cT4cN2M0 | 39 | 41 | 50.4/56 | 28 |
| Pat3 | 71 | M | Larynx | pT1bN0M0 | 34 | 35 | 54/60 | 30 |
| Pat4 | 87 | M | Hypopharynx | cT2cN2bM0 | 33 | 34 | 54/60 | 30 |
| Pat5 | 49 | M | Nasopharynx | cT2cN2bM0 | 40 | 40 | 54/60 | 30 |
| Pat6 | 42 | M | Larynx | pT2bpN1M0 | 44 | 41 | 50.4/56 | 28 |
| Pat7 | 66 | M | Right paranasal sinus | pT2cN0M0 | 31 | 30 | 50.4/61.6 | 28 |
| Pat8 | 67 | M | Left paranasal sinus | pT3N2bM0 | 30 | 30 | 54.4/64 | 32 |
| Pat9 | 76 | M | Nasal cavity | cT3N0M0 | 37 | 38 | 50.4/56 | 28 |
DVH parameters used in this study. Planning risk volumes were used for the brain stem, spinal cord, optic nerves and optic chiasm. D prescr. is the prescription dose. The TPS-specific DVH objectives used in treatment plan optimization are also presented
| Organ at risk or target | DVH parameters evaluated | DVH objectives used for planning |
|---|---|---|
| High dose PTV |
|
|
| High dose CTV |
| |
| Low dose PTV |
|
|
| Low dose CTV |
| |
| Parotid glands |
|
|
| Spinal cord |
|
|
| Brain stem |
|
|
| Optical nerves |
|
|
| Optical chiasm |
|
|
| Eye |
|
|
| Eye lens |
|
|
Fig. 1Dose distributions for Pat2 and Pat5 from the original plan on the pCT and rpCT as well as the adapted dose distributions on the rpCT (rpCTadapt) and vCT (vCTadapt). The high and low dose PTVs are indicated in blue and green respectively. The spinal cord PRV is also shown. For the high dose PTV, the 95 % dose level corresponds to 105 % on the color bar, which is relative to the low dose PTV prescription. Hot spots correspond to 120 % or more of the low dose PTV prescription
Fig. 2DVH curves for Pat2 and Pat5 for the high dose PTV (HD PTV), low dose PTV (LD PTV), left (L) parotid gland and spinal cord PRV for the dose distributions of the initial plan on the pCT, rpCT and the adapted plan on the rpCT (rpCTadapt) and vCT (vCTadapt). The LD PTV excludes the HD PTV volume expanded by a 5 mm margin
Fig. 3Boxplots of target DVH index (D 95 left vertical axis, V 95 right vertical axis) differences. The original (rpCT) and adapted plans (rpCTadapt) on the rpCT are compared to the original plan on the pCT (top panel) and to each other (bottom panel) for the 9 patients investigated in this study. Non-significant differences between original and adapted plan on the rpCT are indicated by ‘n.s.’. All dose values refer to the total dose of the SIB treatment phase for ease of interpretation
Fig. 4Boxplots of target DVH index (D 2) differences. The original (rpCT) and adapted plans (rpCTadapt) on the rpCT are compared to the original plan on the pCT (left panel) and to each other (right panel, including results of the paired Wilcoxon signed-rank test) for the 9 patients investigated in this study. All dose values refer to the total dose of the SIB treatment phase
Fig. 5Boxplots of OAR DVH index differences. The original (rpCT) and adapted plans (rpCTadapt) on the rpCT are compared to the original plan on the pCT (top panel) and to each other (bottom panel, including results of the paired Wilcoxon signed-rank test) for the 9 patients investigated in this study. Left and right eyes, optical nerves and lenses were grouped together for Pat7-9, left and right parotid glands for all patients. All dose values refer to the total dose of the SIB treatment phase for ease of interpretation. Red arrows indicate the cases with most pronounced OAR dose increase from original to adapted plan (see Discussion section)
Fig. 6Boxplots of OAR DVH index differences. The vCT optimized plan on the vCT is compared to the original planning scenario (original plan on pCT) for the 9 patients investigated in this study. Red arrows indicate the cases with most pronounced OAR dose increase for the adapted plan. All dose values refer to the total dose of the SIB treatment phase